Corteva vs Ambev
Global agricultural company supplying seeds and crop protection vs Leading Latin American brewer with extensive distribution network. Which is the better buy for your portfolio in September 2026? Plain-English answer below.
Corteva spun out of DowDuPont to become a pure-play agriculture company with leading seed and crop protection franchises while Ambev brews and distributes beer, soft drinks, and energy drinks across Latin America and Canada. Both companies have durable brand portfolios and compete in industries where volume, pricing, and geographic mix drive annual results. Corteva vs Ambev contrasts an agricultural sciences company's pricing power in seed genetics and herbicide volumes against a beverage giant's market share battles, tax structures, and cash generation in volatile Latin American currencies.
Corteva spun out of DowDuPont to become a pure-play agriculture company with leading seed and crop protection franchises while Ambev brews and distributes beer, soft drinks, and energy drinks across L...
Why It’s Moving
CTVA faces near-term volatility as the Vylor spinoff nears and analysts temper their outlook.
- Corteva’s board approved the planned one-for-one distribution of seed-business shares in Vylor, with the separation targeted for October 1 and a September 24 shareholder record date; the restructuring is creating both potential value clarity and trading-complexity risk.
- BMO Capital Markets reduced its price target to $95 on September 16 while maintaining an Outperform rating, signaling more cautious near-term expectations even as analyst sentiment remains broadly favorable.
- Argus reaffirmed a Buy rating and a $91 price target on September 18, citing improving fundamentals, productivity gains, and stabilizing market conditions; the contrasting analyst actions point to uncertainty around post-spin valuation.
Ambev’s profit engine strengthens as solid margins offset a revenue miss.
- Net revenue increased 6% year over year, but the roughly $3.97 billion result came in below the approximately $4.33 billion analyst estimate, signaling that sales momentum remains a watchpoint.
- Normalized EBITDA rose 9% to about R$6.4 billion and the margin expanded by 80 basis points, showing that cost discipline and mix improvements more than offset higher brand-investment expenses.
- Normalized EPS climbed 24% to R$0.22, while Ambev expanded its wellness portfolio with the Spaten Pro nonalcoholic protein beer and broader distribution of fiber-enriched Guaraná.
CTVA faces near-term volatility as the Vylor spinoff nears and analysts temper their outlook.
- Corteva’s board approved the planned one-for-one distribution of seed-business shares in Vylor, with the separation targeted for October 1 and a September 24 shareholder record date; the restructuring is creating both potential value clarity and trading-complexity risk.
- BMO Capital Markets reduced its price target to $95 on September 16 while maintaining an Outperform rating, signaling more cautious near-term expectations even as analyst sentiment remains broadly favorable.
- Argus reaffirmed a Buy rating and a $91 price target on September 18, citing improving fundamentals, productivity gains, and stabilizing market conditions; the contrasting analyst actions point to uncertainty around post-spin valuation.
Ambev’s profit engine strengthens as solid margins offset a revenue miss.
- Net revenue increased 6% year over year, but the roughly $3.97 billion result came in below the approximately $4.33 billion analyst estimate, signaling that sales momentum remains a watchpoint.
- Normalized EBITDA rose 9% to about R$6.4 billion and the margin expanded by 80 basis points, showing that cost discipline and mix improvements more than offset higher brand-investment expenses.
- Normalized EPS climbed 24% to R$0.22, while Ambev expanded its wellness portfolio with the Spaten Pro nonalcoholic protein beer and broader distribution of fiber-enriched Guaraná.
Investment Analysis
Corteva
CTVA
Pros
- Corteva has shown strong first half 2025 results with raised full-year guidance and a leading North American corn and soybean seed portfolio.
- It leads agricultural innovation with advanced trait technologies, gene editing, hybrid wheat, and digital farming solutions driving long-term growth.
- The company has a robust market position in seeds and crop protection with solid revenue growth and projected operational EBITDA of $3.6-3.8 billion in 2025.
Considerations
- Its stock trades at a premium valuation with a P/E ratio above sector average, indicating potentially limited upside relative to peers.
- Profit margins remain moderate with net margin around 8.16%, which may limit profitability compared to industry standards.
- Recent insider selling and volatility in the stock price pose potential execution and market sentiment risks despite positive earnings.
Ambev
ABEV
Pros
- Ambev is the leading brewer in Latin America with a strong brand portfolio including Brahma, Skol, and Antarctica, offering wide regional market penetration.
- It benefits from consistent cash flow generation supported by high operating margins and effective cost control in a stable beverage sector.
- The company has exposure to growing emerging markets with potential to capitalise on increasing beer and soft drink consumption trends.
Considerations
- Ambev faces regulatory and macroeconomic risks such as tax changes, inflation, and currency fluctuations in Latin American markets.
- The beverage industry is highly competitive and cyclical, exposing Ambev to demand fluctuations and pricing pressure.
- Growth prospects could be constrained by saturation in key markets and limited diversification beyond alcoholic and non-alcoholic beverages.
Corteva (CTVA) Next Earnings Date
Corteva (NYSE: CTVA) is currently expected to report its next earnings on November 3, 2026. The report is expected to cover the third quarter of 2026, ending September 30. This date remains an estimate and has not been formally confirmed by the company.
Ambev (ABEV) Next Earnings Date
Ambev S.A. (ABEV) is expected to release its next earnings report on October 29, 2026. The report will cover the third quarter of fiscal 2026, ended September 30. The date remains an estimate and is consistent with Ambev’s historical pattern of reporting third-quarter results in late October.
Corteva (CTVA) Next Earnings Date
Corteva (NYSE: CTVA) is currently expected to report its next earnings on November 3, 2026. The report is expected to cover the third quarter of 2026, ending September 30. This date remains an estimate and has not been formally confirmed by the company.
Ambev (ABEV) Next Earnings Date
Ambev S.A. (ABEV) is expected to release its next earnings report on October 29, 2026. The report will cover the third quarter of fiscal 2026, ended September 30. The date remains an estimate and is consistent with Ambev’s historical pattern of reporting third-quarter results in late October.
Buy CTVA or ABEV in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
